Opportunity Arises for OVID Investors in Regards to Ovid Therapeutics Inc. Fraud Investigation An Analysis of OVID Investigation Launch by Schall Law Firm

Written By Michael Gary Scott


LOS ANGELES
,

Aug. 2, 2024
/PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, is currently conducting an investigation relating to potential violations of the securities laws by Ovid Therapeutics Inc. (“Ovid” or “the Company”) with ticker symbol OVID.

The inquiry is centered on whether inaccurate statements were made or if crucial information was withheld by the Company. Ovid had publicized on March 30, 2021, that Takeda Pharmaceutical Company Limited (“Takeda”) secured worldwide rights to develop and commercialize its drug candidate soticlestat (TAK-935/OV935). Subsequently, on June 17, 2024, Ovid revealed that “Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency” and that “Takeda’s Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizures.”

Shareholders who have incurred losses are urged to participate in the investigation. The Schall Law Firm, headed by Brian Schall, can be reached at their offices in Los Angeles or through their website for a complimentary discussion of your rights.

Notably, The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering representation to investors across the globe.

It is important to clarify that this press release may be deemed Attorney Advertising in specific jurisdictions based on the relevant legal requirements.

CONTACT:
The Schall Law Firm

Brian Schall, Esq.
310-301-3335
info@schallfirm.com

www.schallfirm.com

Cision
View original content to download multimedia:
Original Source

SOURCE The Schall Law Firm

Market News and Data brought to you by Benzinga APIs


See also  Oracle (ORCL) to Expand Its R&D Capabilities in Morocco